Our services

ADC Review
is made possible by:




PEER-REVIEWED ARTICLES

Addressing Dendritic Cells for Anticancer Immunity

+

By addressing the body’s own immune system the treatment of several severe diseases, e.g. infectious diseases, has become incredibly successful throughout the last centuries. Thus, it is highly desirable to adopt this concept to other diseases as well. Recently, cancer immunotherapy has become an alternative route to treat malignancies effectively without adverse side effects that are usually caused by classical cytostatics.

Read more

Evolution of Antibody-Drug Manufacturing

+

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and processing. With the current availability of 4 commercially approved drugs and approximately 80 programs in various clinical trials, there has been a significant interest in simplifying the complex supply chain.

Read more

Successful Strategies in the Development and Technology Transfer of Antibody-Drug Conjugates

+

In this article, Cynthia Wooge, Ph.D., discusses the requirements of a properly designed technology transfer process and how to ensure a successful transfer and reproducible conjugation process with solid analytics, appropriate engineering design, process (quality) controls and quality assurance. She emphasizes the need to understand which details are critical and how they get effectively communicated between the various parties involved in the transfer process.

Read more

Peer-Reviewed Articles

ADCs – Look Forward to a Potent Future

27 September, 2018

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In this s...

ADCs – The Dawn of a New Era?

26 August, 2018

The technology behind antibody-drug conjugates (ADCs) has been around for many years, but so far is without widespread commercial success. Penelope Drake and ...

Registration of Antibody Drug Conjugates

14 August, 2017

Abstract      Antibody Drug Conjugates (ADC) are a rapidly expanding area of pharma company pipelines. They combine the targeting of an antibody with th...


Skip to toolbar